Schering Aktiengesellschaft

Sterix Limited

Bayer Aktiengesellschaft

Bayer Cropscience Ag

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Olaf Peters

Alexander Hillisch

Christian Gege

Walter Elger

Wilko Regenhardt

Eberhard Unger

Gerhard Siemeister

Dirk Kosemund

Ulrich Bothe

Birgitt Schneider

Jerzy Adamski

Gabriele Moeller

Christopher Hugh Rosinger

Elmar Gatzweiler

Hansjoerg Dietrich

Jens Nagel

Klaus Bernhard Haaf

Bernd Menzenbach

Nico Bräuer

Rolf Bohlmann

Hansjörg Dietrich

Karl-Heinrich Fritzemeier

Guido Bojack

Christa Hegele-Hartung

Anu Bheemaiah Machettira

Sigfrid Schwarz

Thomas Michel

Margit Richter

Ina Scherlitz-Hofmann

Dominga Deluca

Gernot Langer

Katherine Rose Law

Ludwig Zorn

Joachim Kuhnke

Sven Ring

Marcus Koppitz

Jens Hoffmann

Gerd Schubert

Hans-Peter Muhn

Elisabeth Asmus

Stefan Kaulfuss

Thorsten Blume

Stephen David Lindell

Antonius Ter Laak

Gudrun Reddersen

Katja Prelle

Gerd Mueller

Vladimir Patchev

Ina Thieme

Uwe Kollenkirchen

Ingo Tornus

Tobias Neumann

Gerd M&uuml;ller

Andrea Rosinus

Nico Braeuer

Hiroshi Yamanouchi

Gabriele Möller

The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides of general formula (I) and to their agrochemically compatible salts (I) as well as to the use thereof in the field of plant protection.

Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxamides

The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxylic acids and esters of the general formula (I) and their agrochemically acceptable salts and to their use in the crop protection sector.

Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters

The present invention relates to novel benzimidazole derivatives of the general formula (I), to processes for their preparation and to their use for preparing pharmaceutical compositions for the treatment of disorders and indications associated with the EP4 receptor.

Benzimidazole derivatives as EP4 ligands

The present invention relates to novel benzimidazole derivatives of the general formula processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.

Benzimidazole derivatives as EP4 antagonists

The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament. Said compounds have an anti-tumour action. 

2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action

The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I wherein The inventive compounds are distinguished by the 2-alkoxy substitution in conjunction with the 17-hydroxy substitution. They have a special effect with regard to inhibiting tubulin polymerization and can be used, for example, for the treatment of prostate cancers.

Antitumor-active 2-alkoxyestradiol sulfamates

This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homo-substitution. They have a special action with respect to tubulin polymerization inhibition and can be used, for example, for treating prostate cancer

Antitumoral D-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates

The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which

2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17&#x3b2;-hydroxy steroid dehydrogenase type 1

Disclosed are compounds of formula I and use thereof in a method of treating a tumor disease that can be influenced positively by the inhibition of tubulin polymerization.

2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action

The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17&#x3b2;-hydroxy steroid dehydrogenase type 1.

2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17&#x3b2;-hydroxy steroid dehydrogenase type 1

This invention describes the new 8&#x3b2;-substituted estratrienes of general formula I in which R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Rand Rhave the meanings that are indicated in the description, and Rmeans a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8&#x3b2;-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.

8&#x3b2;-hydrocarbyl-substituted estratrienes for use as selective estrogens

This invention relates to 8&#x3b2;-vinyl-11&#x3b2;-(&#x3c9;-substituted)alkyl-estra-1,3,5(10)-trienes of general formula I with ER&#x3b2;-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations that contain the compounds according to the invention, as well as their use for the production of pharmaceutical agents. The new compounds can be used for contraception in men and women without influencing other estrogen-sensitive organs such as the uterus or the liver. They are also suitable for treating benign or malignant proliferative diseases of the ovary, such as ovarian cancer and granulosa cell tumors.

8&#x3b2;-vinyl-11&#x3b2;-(&#x3c9;-substituted)alkyl-estra-1,3,5(10)-trienes

This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homosubstitution. They have a special action with respect to tubulin polymerization inhibition and can be used, for example, for treating prostate cancer 

Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates

Use of ER&bgr;-selective ligands for regulating fertility and compounds useful therefor

Growing community of inventors

Tabarz, Germany

Olaf Peters